Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Dec 19, 2022 7:53pm
132 Views
Post# 35181076

RE: MTX110

RE: MTX110 Looks like some clinical data within about one month against the ultra-rare pediatric brain cancer DIPG. There has already been one phase I trial with 7 patients with remarkable though non-statistically significant results for survival(26 months vs. 10 months). If the results are confirmed in this second study I wonder how strong the read-through is to the glioblastoma trial recently initiated which uses the same drug.  Glioblastoma is a $5 billion market so even a 10% chance of success could be meaningful in terms of value. Average life expectancy for glioblastoma is only 12-18 months so the timeline to outcome once enrolled isn't that long.

"In addition, the company expects to report data in the next couple of months from the second Phase I study assessing MTX110 in DIPG, conducted by Columbia University." Edison Group November 15
Midatech Pharma - Patient recruitment begins in rGBM study | Edison (edisongroup.com)

------

"As a reminder, Midatech had earlier (in October 2020) presented interim data from its other UCSF conducted Phase I study, which not only met its primary endpoint in terms of safety but also demonstrated exceptionally positive early efficacy signals, including median overall survival of 26.06 months (CI 11.3–26.06 months) versus 10 months following standard of care radiation therapy." Midatech Pharma - Interim DIPG data to be presented at ISPNO | Edison (edisongroup.com)


<< Previous
Bullboard Posts
Next >>